Actively Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Led by AstraZeneca · Updated on 2026-05-01
152
Participants Needed
104
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
CONDITIONS
Official Title
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed squamous or non-squamous NSCLC with current Stage IV metastatic disease
- Provide acceptable archival tumor tissue or fresh biopsy if archival tissue is unavailable
- Measurable disease with at least one lesion 10 mm or larger
- Life expectancy of at least 12 weeks as judged by the investigator
- Adequate organ and bone marrow function
- Use contraception according to local regulations during the study
- For Sub-study 2: PD-L1 tumor proportion score of 1% or higher
- For Sub-study 2: Adequate coagulation and urinalysis
- For Sub-study 2: Minimum body weight of 30 kg
You will not qualify if you...
- Known EGFR mutations, ALK fusions, or other genomic alterations with approved first-line targeted therapy
- Presence of small cell or neuroendocrine tumor components
- Severe or uncontrolled systemic diseases, active infections, interstitial lung disease, or symptomatic venous thromboembolism
- Previous stem cell, bone marrow, allogenic tissue, or solid organ transplant
- Active autoimmune disease requiring systemic treatment within the last 5 years
- Significant heart conditions such as arrhythmias, cardiomyopathy, or symptomatic heart failure
- Other primary malignancies unless treated with curative intent and no active disease for 2 years or more
- Persistent toxicities of grade 2 or higher from prior cancer therapy, except hair loss
- Spinal cord compression or symptomatic brain metastases
- Treatment with other anti-cancer agents or immunosuppressants
- Recent palliative radiotherapy to large bone marrow areas
- For Sub-study 2: Active hepatitis A or B, or active hepatitis C infection
- Uncontrolled high blood pressure (systolic ≥150 mm Hg or diastolic ≥100 mm Hg)
- Evidence of major blood vessel or airway invasion by cancer or tumor cavitation
- History of major arterial thrombotic events, severe bleeding, or gross hemoptysis
- Significant bleeding disorders or serious non-healing wounds
- Bowel obstruction, inflammatory bowel disease, or extensive intestinal surgery
- Cirrhosis at Child-Pugh B level or worse, or with related complications
- Prior exposure to certain immune therapies or anti-vascular endothelial growth factor therapies
- Medical contraindication to platinum doublet chemotherapy or ramucirumab
- Known allergy or hypersensitivity to study drugs or their components
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 104 locations
1
Research Site
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
Research Site
Santa Rosa, California, United States, 95403
Actively Recruiting
3
Research Site
Jacksonville, Florida, United States, 32224
Actively Recruiting
4
Research Site
Baltimore, Maryland, United States, 21201
Not Yet Recruiting
5
Research Site
Detroit, Michigan, United States, 48202
Not Yet Recruiting
6
Research Site
Rochester, Minnesota, United States, 55905
Actively Recruiting
7
Research Site
Cleveland, Ohio, United States, 44106
Actively Recruiting
8
Research Site
Providence, Rhode Island, United States, 02903
Actively Recruiting
9
Research Site
Providence, Rhode Island, United States, 02906
Withdrawn
10
Research Site
Tyler, Texas, United States, 75708
Actively Recruiting
11
Research Site
Anderlecht, Belgium, 1070
Not Yet Recruiting
12
Research Site
Hasselt, Belgium, 3500
Not Yet Recruiting
13
Research Site
Leuven, Belgium, 3000
Not Yet Recruiting
14
Research Site
Barretos, Brazil, 14784-400
Not Yet Recruiting
15
Research Site
Fortaleza, Brazil, 60336-232
Not Yet Recruiting
16
Research Site
Natal, Brazil, 59075-740
Not Yet Recruiting
17
Research Site
Pelotas, Brazil, 096015-280
Not Yet Recruiting
18
Research Site
Porto Alegre, Brazil, 90035-903
Not Yet Recruiting
19
Research Site
São Paulo, Brazil, 01246-000
Not Yet Recruiting
20
Research Site
São Paulo, Brazil, 05651-901
Not Yet Recruiting
21
Research Site
Chengdu, China, 610041
Not Yet Recruiting
22
Research Site
Chongqing, China, 400072
Not Yet Recruiting
23
Research Site
Deyang, China, 618000
Not Yet Recruiting
24
Research Site
Fuzhou, China, 350014
Not Yet Recruiting
25
Research Site
Guangzhou, China, 510405
Not Yet Recruiting
26
Research Site
Jinan, China, 250013
Not Yet Recruiting
27
Research Site
Shanghai, China, 200433
Not Yet Recruiting
28
Research Site
Shanghai, China, 201114
Not Yet Recruiting
29
Research Site
Shenyang, China, 110015
Not Yet Recruiting
30
Research Site
Shenzhen, China, 518116
Not Yet Recruiting
31
Research Site
Wuhan, China, 430022
Not Yet Recruiting
32
Research Site
Wuhan, China, 430060
Not Yet Recruiting
33
Research Site
Bordeaux, France, 33076
Not Yet Recruiting
34
Research Site
Dijon, France, 21079
Not Yet Recruiting
35
Research Site
Limoges, France, 87000
Not Yet Recruiting
36
Research Site
Marseille, France, 13015
Not Yet Recruiting
37
Research Site
Nantes, France, 44093
Not Yet Recruiting
38
Research Site
Nice, France, 06189
Not Yet Recruiting
39
Research Site
Paris, France, 75005
Not Yet Recruiting
40
Research Site
Batumi, Georgia, 6010
Not Yet Recruiting
41
Research Site
Tbilisi, Georgia, 0112
Not Yet Recruiting
42
Research Site
Tbilisi, Georgia, 0112
Actively Recruiting
43
Research Site
Tbilisi, Georgia, 0114
Not Yet Recruiting
44
Research Site
Tbilisi, Georgia, 0144
Not Yet Recruiting
45
Research Site
Tbilisi, Georgia, 0186
Withdrawn
46
Research Site
München, Germany, 81675
Not Yet Recruiting
47
Research Site
Münster, Germany, 48149
Withdrawn
48
Research Site
Oldenburg, Germany, 26121
Withdrawn
49
Research Site
Regensburg, Germany, 93053
Not Yet Recruiting
50
Research Site
Würzburg, Germany, 97080
Not Yet Recruiting
51
Research Site
Milan, Italy, 20141
Not Yet Recruiting
52
Research Site
Milan, Italy, 20162
Not Yet Recruiting
53
Research Site
Orbassano, Italy, 10043
Not Yet Recruiting
54
Research Site
Pavia, Italy, 27100
Not Yet Recruiting
55
Research Site
Roma, Italy, 00168
Not Yet Recruiting
56
Research Site
Bunkyō City, Japan, 113-8431
Actively Recruiting
57
Research Site
Bunkyō City, Japan, 113-8677
Actively Recruiting
58
Research Site
Kashiwa, Japan, 277-8577
Actively Recruiting
59
Research Site
Kurume-shi, Japan, 830-0011
Actively Recruiting
60
Research Site
Kyoto, Japan, 602-8566
Actively Recruiting
61
Research Site
Niigata, Japan, 951-8566
Actively Recruiting
62
Research Site
Shinjuku-ku, Japan, 162-8655
Actively Recruiting
63
Research Site
Toyoake-shi, Japan, 470-1192
Actively Recruiting
64
Research Site
Kuala Lumpur, Malaysia, 59100
Actively Recruiting
65
Research Site
Kuala Selangor, Malaysia, 62250
Actively Recruiting
66
Research Site
Kuching, Malaysia, 93586
Actively Recruiting
67
Research Site
Singapore, Malaysia, 329563
Actively Recruiting
68
Research Site
Chisinau, Moldova, MD-2025
Actively Recruiting
69
Research Site
Amsterdam, Netherlands, 1066CX
Not Yet Recruiting
70
Research Site
Groningen, Netherlands, 9713 GZ
Not Yet Recruiting
71
Research Site
Leiden, Netherlands, 2333 ZA
Not Yet Recruiting
72
Research Site
Lima, Peru, 15036
Withdrawn
73
Research Site
Koszalin, Poland, 75-581
Not Yet Recruiting
74
Research Site
Lodz, Poland, 93-338
Not Yet Recruiting
75
Research Site
Olsztyn, Poland, 10-357
Not Yet Recruiting
76
Research Site
Belgrade, Serbia, 11000
Withdrawn
77
Research Site
Kragujevac, Serbia, 34000
Withdrawn
78
Research Site
Niš, Serbia, 18000
Withdrawn
79
Research Site
Seongbuk-Gu, South Korea, 2841
Actively Recruiting
80
Research Site
Seoul, South Korea, 03080
Actively Recruiting
81
Research Site
Seoul, South Korea, 05505
Actively Recruiting
82
Research Site
Seoul, South Korea, 3722
Actively Recruiting
83
Research Site
Seoul, South Korea, 6351
Actively Recruiting
84
Research Site
Barcelona, Spain, 08035
Not Yet Recruiting
85
Research Site
Barcelona, Spain, 08036
Not Yet Recruiting
86
Research Site
L'Hospitalet de Llobregat, Spain, 08908
Not Yet Recruiting
87
Research Site
Madrid, Spain, 28034
Not Yet Recruiting
88
Research Site
Madrid, Spain, 28041
Not Yet Recruiting
89
Research Site
Pamplona, Spain, 31008
Not Yet Recruiting
90
Research Site
Pozuelo de Alarcón, Spain, 28223
Not Yet Recruiting
91
Research Site
Valencia, Spain, 46009
Not Yet Recruiting
92
Research Site
Valencia, Spain, 46010
Not Yet Recruiting
93
Research Site
Taichung, Taiwan, 40201
Actively Recruiting
94
Research Site
Taipei, Taiwan, 110
Actively Recruiting
95
Research Site
Taipei, Taiwan, 11696
Actively Recruiting
96
Research Site
Bangkok, Thailand, 10700
Actively Recruiting
97
Research Site
Chanthaburi, Thailand, 22000
Actively Recruiting
98
Research Site
Hat Yai, Thailand, 90110
Actively Recruiting
99
Research Site
Khon Kaen, Thailand, 40002
Actively Recruiting
100
Research Site
Rachathewi, Thailand, 10400
Actively Recruiting
101
Research Site
Ankara, Turkey (Türkiye), 06230
Not Yet Recruiting
102
Research Site
Ankara, Turkey (Türkiye), 6200
Not Yet Recruiting
103
Research Site
Fatih, Turkey (Türkiye), 34093
Not Yet Recruiting
104
Research Site
Istanbul, Turkey (Türkiye), 34752
Withdrawn
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here